Harbour BioMed’s LET003 obesity drug gets China NMPA IND acceptance
AI Summary- Harbour BioMed said China’s NMPA accepted LET003’s IND application for overweight or obesity.
- LET003 enhanced fat reduction while preserving lean mass when combined with semaglutide in preclinical studies.
- LET003 is Harbour BioMed’s first AI-enabled drug candidate developed using Hu-mAtrIx™.